ECT may be a successful treatment for some cases of tardive dyskinesia. In this review, the authors accumulate all the recent evidence for the efficacy of ECT in treating tardive dyskinesia and make recommendations following data analysis.
In this report, the authors describe the successful management of tardive dyskinesia with quetiapine in a man with schizoaffective disorder and comorbid diabetes with renal and neurologic complications as well as hypothyroidism and hypertension.
What steps do you take when patients exhibit tardive dyskinesia? Are you familiar with treatment guidelines and data on approved and non-approved strategies? Explore recommendations from Dr Daniel Kremens.
Your patient runs out of his antidepressant and a week later his mouth hurts. At presentation, you realize it's because his mouth is constantly twitching and he's been biting his cheeks. He was not taking an antipsychotic, so what's causing it, but more importantly, how do you stop it?
Tardive dyskinesia, a side effect of antipsychotics, is a persistent and disabling problem among patients with schizophrenia. Could a switch to clozapine help? This meta-analysis looks at 16 studies to evaluate the current evidence.
Although levodopa is effective for treating Parkinson disease, physicians and patients face significant management challenges related to disease progression. Patients may develop fluctuations in motor symptoms and dyskinesias as well as nonmotor symptoms. Review this CME Brief Report activity to learn about new and emerging treatment options to manage patients' symptoms.
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”